Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and nonpediatric rheumatologists (2007)

References

• Fink CW. Proposal for the development of classifi cation criteria for the idiopathic arthritides of childhood. J Rheumatol 1995; 22:1566–9.
   PubMed Web of Science ®Google Scholar
• Harrington J. Developmental issues in adolescence and the impact of rheumatic disease. In: Isenberg DA and Miller JJ, editors. Adolescent rheumatology. London: Martin Dunitz; 2000. p. 21–34.
   Google Scholar
• Petty RE, Cassidy JT. Chronic arthritis, poly arthritis, oligoarthritis, systemic arthritis. In: Cassidy JT, Petty RE, Laxer RM, Linsley CB, editors. Textbook of pediatric rheumatology, 5th ed. Philadelphia: Elsevier Saunders; 2005. p. 206–303.
   Google Scholar
• Moe N, Rygg M. Epidemiology of juvenile chronic arthritis in northern Norway: a ten-year retrospective study. Clin Exp Rheumatol 1998;16:99–101.
   PubMed Web of Science ®Google Scholar
• Fujikawa S, Okuni M. A nationwide surveillance study of rheumatic diseases among children. Acta Paediatr Jpn 1997;39:242–4.
   PubMedGoogle Scholar
• Yokota S. Classifi cation of and treatment strategy for juvenile idiopathic arthritis. Therapy 1999;81:766–72.
   Google Scholar
• Pelkonen P, Swanljung K, Siimes MA. Ferritinemia as an indicator of systemic disease activity in children with systemic juvenile rheumatoid arthritis. Acta Paediatr Scand 1986;75:64–8.
   Google Scholar
• De Benedetti F, Massa M, Pignatti P, Albani S, Novick D, Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994;93:2114–9.
   PubMed Web of Science ®Google Scholar
• Rooney M, David J, Symons J, Di Giovine F, Varsani H, Woo P. Infl ammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995;34:454–60.
   Google Scholar
• Hollingworth P. The use of non-steroidal anti-infl ammatory drugs in paediatric rheumatic diseases. Br J Rheumatol 1993;32: 73–7.
   PubMedGoogle Scholar
• Adebajo AO, Hall MA. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br J Rheumatol 1998;37:1240–2.
   PubMedGoogle Scholar
• Aouali N, Eddabra L, Macadr� J, Morjani H. Immunosuppressors and reversion of multidrug-resistance. Crit Rev Oncol Hematol 2005;56:61–70.
   PubMed Web of Science ®Google Scholar
• Gottlieb BS, Keenan GF, Lu T, Ilowite NT. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics 1997;100:994–7.
   PubMed Web of Science ®Google Scholar
• Wilkinson N, Jackson G, Gardner-Medwin J. Biologic therapies for juvenile arthritis. Arch Dis Child. 2003;88:186–91.
   Google Scholar
• Wallace CA, Ruperto N, Giannini E. Preliminary criteria for clinical remission for select categories for juvenile idiopathic arthritis. J Rheumatol 2004;31:2290–4.
   Google Scholar
• Yokota S. IL-6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 2003;15:581–6.
   PubMed Web of Science ®Google Scholar
• Stephan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol 1993;11: 451–6.
   PubMed Web of Science ®Google Scholar
• Malagon C, Van Kerckhove C, Giannini EH, Taylor J, Lovell DJ, Levinson JE, et al. The iridocyclitis of early onset pauciarticular juvenile rheumatoid arthritis: outcome in immunogenetically characterized patients. J Rheumatol 1992;19:160–3.
   PubMed Web of Science ®Google Scholar
• Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti- CCP). Ann Rheum Dis 2004;63:1090–5.
   Google Scholar
• Low JM, Chauhan AK, Kietz DA, Daud U, Pepmueller PH, Moore TL. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol 2004;31:1829–33.
   PubMed Web of Science ®Google Scholar
• Giannini EH, Cassidy JT. Methotrexate in juvenile rheumatoid arthritis: do the benefi ts outweigh the risk? Drug Saf 1993;9: 325–39.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgwood RJ. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989;32:677–81.
   PubMedGoogle Scholar
• Woo P, Southwood TR, Prieur AM, Dor� CJ, Grainger J, David J, et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum 2000;43:1849–57.
   Google Scholar
• Ramanan AV, Whitworth P, Baildam EM. Use of methotrexate in juvenile idiopathic arthritis. Arch Dis Child 2003;88:197–200.
   PubMed Web of Science ®Google Scholar
• Kashiwazaki S, Ichikawa Y, Sugawara S, Nagaya I, Kawai S, Hakota M, et al. Determination of the clinical optimal dose of. L-377 (methotrexate capsule) for the treatment of rheumatoid. arthritis (in Japanese). Ensho 1996;16:437–58.
   Google Scholar
• Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile arthritis: results of the USA-USSR double-blind placebo-controlled trial. N Engl J Med 1986;314:1269–76.
   PubMed Web of Science ®Google Scholar
• Cassidy JT. Outcomes research in the therapeutic use of methotrexate in children with chronic peripheral arthritis. J Pediatr 1998;133:179–80.
   Google Scholar
• Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic effi cacy of multiple intravenous infusions of anti-tumor necrosis factor alpha antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552–63.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile RA. N Engl J Med 2000;342:763–9.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T, Yosh izaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 2000;59: Suppl 1:21–7.
   Google Scholar
• 2002/016 NICE recommends the selective use of new drugs for arthritis in children and adults. http://guidance.nice.org.uk/page. aspx?o-29666
   Google Scholar
• Miyasaka N, Takeuchi T, Eguchi K. Proposed Japanese guidelines for the use of infl iximab for rheumatoid arthritis. Mod Rheumatol 2005;15:4–8.
   Google Scholar
• Yokota S, Mori M, Imagawa T, Takei S, Murata T, Tomiita M, et al. Juvenile idiopathic arthritis: guidance for primary care (2007) (in Japanese). J Jpn Pediatr Soc 2007;111:1103–12.
   Google Scholar